✦ LIBER ✦

Oupatient Lenalidomide Desensitization For Delayed Hypersensitivity Reactions In 5 Patients With Multiple Myeloma

✍ Scribed by Lee, Min Jung; Wickner, Paige G.; Schlossman, Robert; Richardson, Paul; Laubach, Jacob; Castells, Mariana C.

Book ID: 122762257
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 41 KB
Volume: 133
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2013.12.977

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Desensitization to Lenalidomide in a Pat

Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma

✍ Seki, Jack T.; Banglawala, Sabiha; Lentz, Emily M.; Reece, Donna E. 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 199 KB

Transient inflammatory reaction during l

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma

✍ Shuji Ozaki; Takeshi Harada; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Ayako 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 254 KB

Lenalidomide for multiple myeloma: cost-

Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

✍ Brown, Ruth E.; Stern, Sean; Dhanasiri, Sujith; Schey, Steve 📂 Article 📅 2012 🏛 Springer 🌐 French ⚖ 255 KB

Lenalidomide Is Effective for the Treatm

Lenalidomide Is Effective for the Treatment of Bortezomib-Resistant Extramedullary Disease in Patients With Multiple Myeloma: Report of 2 Cases

✍ Ito, Chisako; Aisa, Yoshinobu; Mihara, Ai; Nakazato, Tomonori 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 982 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Enoxaparin or aspirin for the prevention

Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide

✍ A. PALUMBO; C. RUS; J. B. ZELDIS; F. RODEGHIERO; M. BOCCADORO; THE ITALIAN MULTI 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB